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Abstract
Objective—To examine associations between lipids (HDL, LDL, total cholesterol, triglycerides,
lipoprotein (a)) measured on average three time-points during pregnancy and neonatal
anthropometrics.
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Study Design—Stored samples from a preeclampsia trial measured as part of a case-control
study from five US centers (1992-1995) were used. The sample included women without
pregnancy complications (n=136), and cases of gestational diabetes (n=93), abnormal glucose
tolerance (n=76), gestational hypertension (n=170), and preeclampsia (n=177). Linear regression
and linear mixed-effects models estimated adjusted associations between lipids and birth weight zscore, ponderal index, length, and head circumference.
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Results—Among women without complications, cross-sectional associations between total
cholesterol measured at different gestational ages increased ponderal index 2.23 to 2.55 kg/m3 perunit increase in cholesterol. HDL was inversely associated with birth length (β's=-2.21 and -2.56
cm). For gestational hypertension, triglycerides were associated with birth weight z-score
(β's=0.24 to 0.31). For preeclampsia, HDL was associated with lower birth weight z-scores
(β's=-0.49 and -0.82). Women with gestational diabetes or abnormal glucose tolerance had
inconsistent associations. Examining the level changes across pregnancy, each 0.0037 mmol/L
increase in HDL was associated with decreased birth weight z-score (β=-0.22), length (β=-0.24
cm), and head circumference (β=-0.24 cm) whereas each 0.028 mmol/L increase in triglycerides
was associated with increased birth weight z-score (β=0.13) and head circumference (β=0.19 cm).
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Conclusion—Although associations varied by complications, in general, growth promoting fuels
as total cholesterol and triglycerides were associated with increased neonatal size whereas high
HDL was associated with smaller size. Maternal HDL that failed to decrease over pregnancy was
associated with smaller neonate size.
Keywords
Maternal lipids; Newborn; Ponderal index; birth weight z-score; birth length; birth head
circumference

Introduction
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Inappropriate fetal growth, often assessed by birth weight, has an important effect on the
future risk of coronary heart disease, hypertension, and type 2 diabetes.1 While the impact of
hyperglycemia in pregnancy, particularly in overt gestational diabetes, on fetal growth is
well documented,2-4 studies examining associations between other maternal fuels and
newborn size, however, have been limited. The majority of the studies examined lipid
biomarkers measured at one time point during pregnancy while restricting the study sample
to diabetic pregnancies, non-diabetic pregnancies with positive diabetic screens, or
uncomplicated pregnancies.5-11 Findings from these studies have been inconsistent. We
sought to understand whether the heterogeneity in previous findings were due to having
different timing of specimens, different case mix group of women with and without
complications or the specific measure of neonatal size evaluated. Furthermore, studies did
not have multiple measures from both before and after the clinical diagnosis of these
conditions. Lipid biomarkers, if proven useful, may also be relatively easy to implement in
clinical settings as hospital laboratories are already equipped to measure lipids for the
purpose of cardiovascular screening in non-pregnant populations. We examined whether
maternal circulating fuels, measured on average at three time points during pregnancy,
influenced neonatal size stratifying by common pregnancy complications (i.e. gestational
diabetes, abnormal glucose tolerance, gestational hypertension, preeclampsia, or no reported
pregnancy complications) and adjusting for other maternal factors known to impact fetal
growth.

Materials and Methods
Study population
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The study population was derived from the Calcium for Preeclampsia Prevention (CPEP)
trial, a randomized double-blind clinical trial (1992-1995) conducted among 4,589 healthy
nulliparous women with singletons pregnancies and without preexisting hypertension or
proteinuria across 5 US centers to examine the impact of calcium supplementation on the
incidence and severity of preeclampsia.12 Women were randomized at a gestational age
between 13 weeks 0 days to 21 weeks 6 days as determined from the earliest obstetrical
ultrasound.12 Details of the study have been published elsewhere.12 The trial showed no
effect of calcium on the risk or severity of preeclampsia.13 The final sample size included
3,667 women after excluding women who were lost to follow-up (n=283), those who had a
pregnancy loss (n=49), had an infant with a chromosomal abnormality (n=1), or had no
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blood collected during the baseline screening visit or misdated samples (n=589).14 We
measured lipids as part of a nested case-control study to examine biomarkers associated with
risk of pregnancy complications.15 Given the use of existing de-identified samples, this
study was exempted from Institutional Review Board review and approved by the National
Institutes of Health's Office of Human Subjects Research.
Pregnancy complications strata

Author Manuscript

The “normal” group free of pregnancy complications (n=136) consisted of a random group
of women who were normoglycemic, normotensive, without proteinuria, and who delivered
a term, not small for gestational age infant. The pregnancy complication strata included
women with gestational diabetes (GDM; n=93), abnormal glucose tolerance (i.e., having an
initial positive diabetic screen followed by a normal glucose tolerance test) (n=76),
gestational hypertension (n=170), and preeclampsia (n=177). Women with more than one
pregnancy complication were included in each group accordingly. Detailed definitions of
preeclampsia and gestational hypertension diagnosis are published elsewhere.13,14,16 Briefly,
preeclampsia was defined as pregnancy associated hypertension, a diastolic blood pressure
≥90 mmHg on two different occasions 4 to 168 hours apart, and proteinuria, characterized as
one of the following: a urine dipstick of at least 1+ (30 mg per deciliter) on two occasions (4
to 168 hours apart), a urine dipstick of at least 2+ (100 mg per deciliter), a protein:creatinine
ratio ≥0.35, or a 24-hour urine specimen with ≥300 mg of protein. Gestational hypertension
used the same cutoffs of diastolic blood pressure with no proteinuria. Gestational diabetes
was defined according to the American Diabetes Association 1997 criteria, with a plasma
glucose >200 mg/dl 1-hour after 50g glucose challenge test (GCT) without an oral glucose
tolerance test (OGTT), or a 50g GCT result >140 mg/dl at 1-hour and two abnormal values
on the 3-hour 100-gram OGTT.17 The OGTT cutoffs were ≥95 mg/dL fasting, ≥180 mg/dL
at 1-hour, ≥155 mg/dL at 2-hours, and ≥140 mg/dL at 3-hours. Abnormal glucose tolerance
(AGT) was defined as those who failed the 50g GCT but had a subsequent normal OGTT.
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Covariates
At enrollment, women self-reported their age, race/ethnicity (Non-Hispanic White, NonHispanic Black, Hispanic or other), smoking status, education, insurance status, and marital
status. Body mass index (BMI) was calculated based on weight measured during the
screening visit before 21 weeks' gestation and self-reported height.
Outcomes
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The baby's birth weight, length, and head circumference were abstracted from medical
records. Ponderal index (PI) was calculated as [birth weight (g) × 100/(crown heel length
(cm))3]. Birth weight z-score was defined according to US tables that account for race,
parity, gestational age, and sex of the infant.18 Large for gestational age (LGA) was defined
as birth weight above the 90th percentile for gestational age.18 Gestational age was verified
by ultrasound data from before enrollment.
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Lipid measurement
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Non-fasting maternal blood samples were taken at the baseline visit prior to randomization
(any time before 21 weeks and 6 days of gestation) and on average twice during follow-up.
Serum samples were frozen and stored at -70°C for 17-21 years. Low and high density
lipoprotein (LDL, HDL), total cholesterol, triglycerides, and lipoprotein (a) (Lp(a)) were
measured by Roche Modular P chemistry analyzer (Roche Diagnostics, Indianapolis, IN)
with coefficients of variation <4%. At higher levels of Lp(a) (≥47 mg/dl), the coefficient of
variation was 6.5%. In total, 1640 serum samples from 595 women (n=39 women with 1
sample, n=123 with 2 samples, n=378 with 3 samples, n=54 with 4 samples, and n=1 with 5
samples) were sent for measurement of lipids.
Statistical methods
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We described first maternal and neonatal characteristics, represented by mean (SD) or n (%)
as appropriate, by pregnancy complication group. We also examined the lipid biomarker
means across gestation (<22, 22-32, 33-42 weeks) by pregnancy complication group. Linear
regression models were used to examine if significant differences existed in the lipid
biomarker means across the three measurement time points during pregnancy and when
comparing women in each pregnancy complication group to women in the control group.
Correlations between lipid measurements and maternal BMI were estimated by Pearson
correlation coefficient. We subsequently examined associations between each maternal lipid
biomarker and neonatal anthropometry cross-sectionally at <22 weeks, 22-32 weeks, and
33-42 weeks using linear regression models adjusting for maternal ethnicity/race (NonHispanic white, non-Hispanic black, and Hispanic or other), current smoker (yes/no), and
BMI (continuous) stratifying by each pregnancy complication to eliminate potential biases
in the association between maternal metabolic factors and newborn anthropometrics. Women
with preeclampsia, for example, may have growth-restricted infants due to placental
insufficiency rather than metabolic factors. We additionally adjusted for gestational age for
models evaluating PI, length, and head circumference as outcomes. We also evaluated the
odds ratios and 95% confidence intervals (CI) of being born LGA in association with
maternal hypertriglyceridemia (triglyceride levels >75th percentile value based on all serum
measures across gestation) cross-sectionally at <22 weeks, 22-32 weeks, and 33-42 weeks
using logistic regression analyses and adjusting for the same above variables. Using linear
mixed-effects models, we subsequently assessed the lipid measurements across pregnancy
by examining how the lipid trajectory (individual slopes) is associated with the examined
newborn anthropometrics. No adjustments were made for multiple testing but we mark in
tables associations with Bonferroni corrected p-values of <0.01 in place of <0.05 for
statistical significance due to evaluating 5 lipid biomarkers that may have overlapping
pathways (0.05/5). All analyses were conducted using SAS 9.3 and R 3.1.
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Results
Table 1 shows the characteristics of the mothers and their infants. On average, the women
were 21 years old and with a BMI of 27.1 kg/m2 at the screening visit. Around 50% were
Black, and the majority were not married (76%) and had no private insurance (90%).
Triglycerides and Lp(a) were weakly correlated with maternal BMI (r=0.10, p<0.001;
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r=0.08, p=0.001, respectively) while no significant correlations were detected for LDL and
total cholesterol. Maternal BMI was inversely related to HDL-cholesterol (r=-0.12,
p<0.001).
Mean levels of all the examined biomarkers differed significantly across pregnancy except
for HDL and Lp(a) (Table 2). HDL was higher at the baseline measurement <22 weeks in
comparison to the final measurement at 33-42 weeks while Lp(a) did not show any changes
across gestation. Compared to women without pregnancy complications, women with GDM
had lower levels of total cholesterol, HDL, and LDL but higher levels of triglycerides while
women with gestational hypertension had lower levels of total cholesterol and LDL but
higher levels of triglycerides. Women with preeclampsia or AGT in comparison to women
without pregnancy complications had similar levels of all the lipid biomarkers except for
triglycerides.
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Table 3 shows only the significant associations between maternal lipid biomarkers and
neonatal anthropometrics by pregnancy complication group at the three time point
measurements across gestation. In general, total cholesterol, LDL, and triglycerides were
associated with greater growth whereas HDL was associated with less growth. However,
some variability in the associations was observed between women with different pregnancy
complications depending on the type of lipid biomarker, timing of the measurement, and
anthropometric measure evaluated. Specifically, among women without pregnancy
complications, total cholesterol was consistently associated with PI at all three
measurements across gestation; a 1 unit increase in cholesterol increased the PI by 2.23-2.55
kg/m3 independent of maternal factors. HDL was associated with decreased length at
baseline and near delivery. Other associations at single time points were also observed but
no associations were detected with Lp(a).
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Among women with GDM, only lipid measures taken late in pregnancy were associated
with neonatal size. In particular, HDL was associated with a lower birth weight z-score
(β=-1.16, 95% CI: -1.92, -0.40) while triglycerides were associated with higher birth weight
z-score (β=0.21, 95% CI: 0.0010, 0.42). Among women with gestational hypertension,
triglycerides were consistently associated with birth weight z-score regardless of time of
measurement (β=0.24 to 0.31). Total cholesterol and LDL were also associated with greater
size measures. Among women with preeclampsia, second and third HDL measurements
were associated with decreased birth weight z-score (β=-0.49 to -0.82) and decreased PI
(β=-1.50 to -2.56 kg/m3) while only the third measurement was associated with head
circumference (β=-1.33 cm). Other sporadic associations were noted with LDL and Lp(a).
Very few associations were detected between maternal lipid biomarkers and neonatal
anthropometrics among women with AGT. Only HDL at the first measurement was
associated with head circumference (β=1.28 cm; 95% CI: 0.10, 2.47) while HDL at the
second measurement was associated with decreased PI (β=-3.00 kg/m3; 95% CI: -5.90,
-0.11) (data not shown). When we examined maternal hypertriglyceridemia (triglyceride
levels >75th percentile value; 2.69 mmol/L) in association with LGA, we found no
significant associations in any of the pregnancy complication groups.
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Given the similarities in patterns of change for each lipid measured between women with
different pregnancy complications (Table 2), we examined the change in lipid levels
grouping all women but also additionally adjusting for the type of pregnancy complication.
Examining the longitudinal lipid measurements with the neonatal anthropometric measures
shows that a 0.0037 mmol/L increase in HDL across pregnancy was associated with
decreased birth weight z-score (β=-0.22, 95% CI: -0.30, -0.14), length (β=-0.24 cm, 95%
CI: -0.46, -0.015), and head circumference (β=-0.24 cm, 95% CI: -0.38, -0.11), while a
0.028 increase in triglycerides was associated with increased birth weight z-score (β=0.13,
95% CI: 0.034, 0.22) and head circumference (β=0.19 cm, 95% CI: 0.040, 0.34). Adjusting
for pregnancy complications did not change any of the estimates. None of the other
trajectories of total cholesterol, LDL, and Lp(a) were associated with neonatal
anthropometric measures (data not shown).
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Discussion
Main Findings
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We examined the dynamic changes of lipid levels across gestation and the cross-sectional
associations between maternal fuels measured on average at three time points during
pregnancy and neonatal anthropometrics among women with uncomplicated and
complicated pregnancies. Cross-sectional associations varied by pregnancy complication
group and the timing of the measurement, which may be a function of whether the
measurement was taken before or after the clinical diagnosis of the complication and sample
sizes of each group. However, in general, total cholesterol and triglycerides levels promoted
growth while HDL levels were associated with smaller size. Women with GDM or AGT had
very minimal associations between maternal lipid levels and neonatal anthropometrics,
suggesting that glucose levels or other factors may have a more dominant impact on
newborn size. Examining the longitudinal associations between lipids and neonatal
anthropometrics after adjusting for pregnancy complications shows smaller size with
increasing HDL levels and a higher birth weight z-score with increasing triglycerides across
pregnancy.
Strengths and limitations
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Strengths of our current study include the different groups of pregnancy complications that
were examined and the measurements at different time points. We also add to the previous
literature by examining the PI instead of birth weight alone. It has been postulated that
compared to birth weight, the PI might be a better marker of future cardiovascular health as
it reflects different temporal patterns of fetal undernutrition.19 Our study was limited by the
lack of fasting blood samples. However, total and HDL cholesterol levels were unlikely
severely impacted by fasting status.20 Fasting time would not be associated with either
neonatal anthropometry or complication status, but such random error may have reduced
associations to the null. CPEP also recruited nulliparous women, who were young and with
the majority being African American, which is not representative of all US pregnancies.
BMI was also measured in early pregnancy.
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Interpretation
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The evidence of the impact of lipid levels on newborn size among women with no pregnancy
complications has been inconsistent with some suggestion of differences due to prepregnancy BMI. One study found that triglycerides were associated with higher birth weight
adjusted for gestational age but only among normal weight women while HDL was
associated with inverse size but only among overweight/obese women.21 On the other hand,
the Pregnancy Outcomes and Community Health (POUCH) study (n=1207) found that total
cholesterol was associated with birth size in normal weight women but HDL and
triglycerides in overweight/obese women (adjusting for pregnancy complications).9 Since
there was inconsistent evidence and our sample size for non-complicated women was small,
we adjusted rather than stratified by BMI among our study controls. Even so, associations
differed slightly also by timing of measurement, and we only observed a consistent
association between PI and total cholesterol and an inverse association between length and
HDL. Among undernourished Indian women, total cholesterol measured at 18 and 28 weeks'
gestation was associated with birth weight independent of maternal factors such as dietary
intake and other maternal fuels including fasting glucose, HDL, and triglyceride.22 In a
Norwegian study, an inverse association was observed with HDL which persisted even after
adjusting for gestational weight gain whereas a positive association between triglycerides
and skinfolds (but not birth weight) was found but only after excluding women diagnosed
with GDM.23 Yet other studies have shown more consistent associations between birth
weight or LGA and triglycerides but not with total cholesterol.24,25 These inconsistent
associations across studies suggest that lipid measurements are unlikely to add sufficient
evidence to inform practice with regards to fetal growth. HDL, which is not as subject to
differences in fasting status,20 might have been a good candidate lipid biomarker but even
this measure did not have consistent associations as reviewed above. Perhaps what is more
important is the trajectory of HDL, which normally decreases during pregnancy. We find
that when HDL does not decrease as it should, it may be an indicator of smaller size at birth
as observed in our longitudinal models.
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In our examination of women with hypertensive disorders, we found different results
depending on the severity of hypertension and timing of measurement. As CPEP was a trial
of preeclampsia, women with blood pressure >135/85 mmHg were excluded from
participation.12 As such, lipid measures at baseline reflect values prior to clinical diagnosis
of hypertension or preeclampsia. These associations, however, still differed from the control
group and only among women with gestational hypertension were consistent associations
observed between triglycerides and the birth weight z-score. While studies have noted that
women with gestational hypertension have higher triglyceride levels than women without
gestational hypertension,26 no previous studies to our knowledge have examined how
maternal lipid biomarkers are associated with newborn anthropometrics among women with
gestational hypertension. Interestingly, only women with preeclampsia showed associations
between Lp(a) and two of the examined newborn measures including birth weight z-score
and length. Worth noting is that one third of the women with preeclampsia delivered a
preterm infant.
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Lipoprotein (a), a carrier of cholesterol, has been associated with increased risk of a variety
of cardiovascular disorders.27 As preeclampsia has some features of coronary heart disease,
several studies have addressed the role of Lp(a) in preeclampsia.28 The role of Lp(a) in
either normal or complicated pregnancies however, has been less conclusive. Two metaanalyses concluded that the equivocal evidence has been a result of the different methods
used in measuring Lp(a), the sample size, study design, and ethnicity of the study
population.28,29 To our knowledge, the Lp(a) association with neonatal anthropometrics has
not been explored previously.
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The minimal associations observed for women with GDM or AGT might be due to the
overwhelming effects of plasma glucose.30 In a study of over 2200 mother-baby pairs (20%
with GDM), first visit fasting plasma glucose (10-24 weeks' gestation) was associated with
birth weight and birth length.4 In a subsequent study among over 1500 mother-baby pairs by
the same group, first visit triglycerides were also positively associated with birth weight and
head circumference.8 Contrary to our findings for the AGT group, two previous studies of
nondiabetic women (n=146 and n=83) with a positive diabetic screen found associations
between birth weight and triglyceride levels.5,6 Both studies further found that maternal
hypertriglyceridemia, defined as triglyceride levels above the 75th percentile, was associated
with having an LGA infant at term5,6 with one study showing hypertriglyceridemia >259
mg/dl (OR=11.6; 95% CI: 1.1, 122) to be an independent predictor of LGA after accounting
for other maternal factors including prepregnancy BMI and fasting plasma glucose levels.6
The lack of association with LGA in our study might be due to sample size limitations as we
only had 67 women with AGT measured between 22-32 weeks' gestation with only 11
women having triglyceride levels above 259 mg/dl. Similarly, defining hypertriglyceridemia
as the 75th cutpoint for our sample did not impact the results (data not shown). Among
women with GDM (n=150), maternal triglycerides measured during the 3rd trimester
correlated significantly with newborn fat mass (r=0.17, p=0.03) but not with birth weight or
neonatal BMI.11 Additionally, maternal triglycerides at delivery remained associated with
LGA independent of maternal BMI.11 Associations between maternal serum triglyceride
levels measured in early pregnancy and at 24-28 weeks' gestation and birth weight ratio
(birth weight corrected for gestational age) independent of maternal factors however, have
been reported in other studies.31,32

Conclusion
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Despite general observations that HDL was associated with reduced neonatal size while total
cholesterol and triglycerides may be associated with larger size, our findings in combination
with evidence from the literature suggest that lipid biomarkers are not likely to serve as
clinically useful markers of fetal growth and are unlikely to change clinical decision making.
The onset of pregnancy complications, especially GDM and preeclampsia, appeared to
further deteriorate the ability of the lipid biomarkers to predict neonatal size. Pooling
individual data across studies may serve as one way to tease apart the utility of these
markers. All data from this study are being made available to further such investigations.
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AGT

abnormal glucose tolerance

BMI

body mass index

CPEP

Calcium for Preeclampsia Prevention

GCT

glucose challenge test

J Perinatol. Author manuscript; available in PMC 2017 September 23.

Boghossian et al.

Page 11

Author Manuscript

GDM

gestational diabetes

LGA

large for gestational age

OGTT

oral glucose tolerance test

PI

ponderal index
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49.7 (3.8)
33.7 (2.3)

Ponderal index (kg/m3)

Length (cm)

Head circumference (cm)
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15.9 (3.2)
27.7 (3.1)
35.8 (1.7)

Gestational age at collection of 1st sample
(wk)

Gestational age at collection of 2nd sample
(wk)

Gestational age at collection of 3rd sample
(wk)

36.2 (0.9)

28.3 (3.3)

15.6 (2.6)

39.3 (1.52)

6 (4.4)

9 (6.6)

0 (0.0)

0.06 (0.79)

34.2 (2.0)

50.2 (3.5)

26.9 (9.5)

3314 (445)

63 (46.3)

10 (7.4)

25.5 (5.6)

118 (86.8)

60 (44.1)

30 (22.1)

26 (19.1)

63 (46.3)

47 (34.6)

20.4 (3.7)

Controls N=136

35.7 (1.5)

27.7 (3.0)

16.0 (2.7)

38.6 (1.7)

7 (7.5)

15 (16.1)

4 (4.3)

0.44 (1.2)

34.4 (1.7)

50.7 (3.1)

26.4 (6.3)

3424 (583)

50 (53.8)

20 (21.5)

29.9 (6.5)

79 (85.0)

32 (34.4)

35 (37.6)

10 (10.8)

32 (34.4)

51 (54.8)

23.8 (6.1)

Gestational diabetes1 N=93

Data missing for: married: 1, education: 2, ponderal index: 32, length: 32, head circumference: 31

Figures are means (SD) unless otherwise specified

87 (14.6)
38.5 (2.5)

Gestational age at delivery (wk)

52 (8.7)

LGA n (%)

Preterm birth <37 weeks n (%)

55 (9.2)

SGA n (%)

-0.0083 (1.1)

25.7 (6.0)

Birth weight (g)

Birth weight z-score

296 (49.8)
3163 (692)

Male infant n (%)

73 (12.3)

Current smoker n (%)

Body mass index

535 (89.9)

No private insurance n (%)
27.1 (6.3)

246 (41.5)

(kg/m2)

143 (24.1)

Less than high school n (%)

90 (15.1)

Married n (%)

285 (47.9)

Hispanic or other race

220 (37.0)

21.3 (4.8)

Total N=595

Non-Hispanic Black

Non-Hispanic White

Race/ethnicity n (%)

Age (years)

Characteristic

36.1 (0.96)

27.7 (3.0)

15.7 (2.6)

39.1 (1.3)

2 (2.6)

6 (7.9)

7 (9.2)

-0.072 (0.93)

34.4 (1.7)

50.7 (3.1)

26.2 (3.4)

3248 (453)

34 (44.7)

14 (18.4)

25.8 (4.9)

65 (85.5)

29 (38.2)

20 (26.3)

14 (18.4)

32 (42.1)

30 (39.5)

21.6 (4.3)

Abnormal glucose
tolerance2 N=76

35.3 (2.4)

27.6 (3.5)

16.2 (4.5)

37.3 (3.0)

59 (33.3)

9 (5.1)

33 (18.6)

-0.30 (1.1)

33.1 (2.8)

48.6 (4.3)

24.4 (3.4)

2853 (818)

91 (51.4)

22 (12.4)

28.0 (6.4)

166 (93.8)

76 (43.4)

37 (20.9)

29 (16.4)

95 (53.7)

53 (29.9)

20.8 (4.4)

Preeclampsia3 N=177

35.9 (1.6)

27.4 (2.7)

15.8 (2.4)

38.7 (2.6)

16 (9.4)

19 (11.2)

14 (8.2)

0.10 (1.14)

33.8 (2.4)

50.0 (3.8)

25.5 (3.7)

3244 (716)

88 (51.8)

18 (10.6)

27.1 (6.6)

158 (92.9)

74 (43.5)

37 (21.9)

20 (11.8)

88 (51.8)

62 (36.5)

21.2 (5.1)

Gestational hypertension4 N=170
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Characteristics of study participants by pregnancy complication group in the CPEP Study
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Of the 170 women with gestational hypertension, 22 also had gestational diabetes.

4

Of the 177 women with preeclampsia, 14 also had gestational diabetes.

3

Of the 76 women with abnormal glucose tolerance, 5 also had preeclampsia and 16 also had gestational hypertension.

Of the 93 women with gestational diabetes, 14 also had preeclampsia and 22 also had gestational hypertension.
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2

Author Manuscript

1
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Table 2

Author Manuscript

Means of lipid biomarkers across gestation by pregnancy complication group in the CPEP
Study
Pregnancy complication group

p-value1

<22 weeks

22-32 weeks

33-42 weeks

N=136

N=116

N=113

Total Cholesterol mmol/L

5.18 (0.90)

6.23 (0.99)

6.64 (1.25)

HDL mmol/L

1.59 (0.34)

1.64 (0.34)

1.49 (0.35)

0.0079

LDL mmol/L

3.06 (0.85)

3.91 (0.95)

4.17 (1.30)

<0.0001

Triglycerides mmol/L

1.43 (0.46)

1.99 (0.69)

2.76 (0.94)

<0.0001

Lipoprotein A μmol/L

1.45 (1.58)

1.60 (1.70)

1.65 (1.97)

0.62

N=92

N=82

N=76

Total Cholesterol mmol/L

5.27 (1.06)

5.84 (1.1)2

6.20 (1.29)2

<0.0001

HDL mmol/L

1.49 (0.31)2

1.48 (0.30)3

1.37 (0.33)2

0.032

LDL mmol/L

3.06 (0.91)

3.38 (1.07)3

3.62 (1.10)2

0.002

Triglycerides mmol/L

1.79 (0.82)3

2.70 (1.30)3

3.11 (1.26)2

<0.0001

Lipoprotein A μmol/L

1.18 (1.26)

1.22 (1.47)

1.32 (1.51)

0.79

Abnormal glucose tolerance

N=76

N=67

N=63

Total Cholesterol mmol/L

5.29 (0.79)

6.20 (1.12)

6.47 (1.29)

<0.0001

HDL mmol/L

1.57 (0.29)

1.54 (0.36)

1.46 (0.33)

0.14

LDL mmol/L

3.14 (0.75)

3.91 (1.12)

4.00 (1.25)

<0.0001

Triglycerides mmol/L

1.54 (0.57)

2.29 (0.80)2

2.86 (0.93)

<0.0001

Lipoprotein A μmol/L

1.33 (1.3)

1.57 (1.59)

1.42 (1.42)

0.61

N=170

N=149

N=136

Total Cholesterol mmol/L

5.12 (0.97)

6.00 (1.09)

6.29 (1.3)2

HDL mmol/L

1.56 (0.34)

1.59 (0.38)

1.46 (0.38)

0.013

LDL mmol/L

2.98 (0.87)

3.62 (1.10)2

3.75 (1.21)2

<0.0001

Triglycerides mmol/L

1.52 (0.66)

2.28 (1.12)2

2.96 (1.23)

<0.0001

Lipoprotein A μmol/L

1.20 (1.19)

1.37 (1.35)

1.29 (1.36)

0.51

N=166

N=152

N=125

Total Cholesterol mmol/L

5.17 (1.04)

6.10 (1.29)

6.43 (1.70)

HDL mmol/L

1.54 (0.32)

1.59 (0.38)

1.47 (0.36)

0.025

LDL mmol/L

3.04 (0.89)

3.73 (1.21)

3.83 (1.49)

<0.0001

Triglycerides mmol/L

1.50 (0.65)

2.22 (0.89)2

2.93 (1.23)

<0.0001

Lipoprotein A μmol/L

1.51 (1.34)

1.75 (1.62)

1.66 (1.59)

0.37

Controls

Gestational diabetes mellitus

Author Manuscript
Author Manuscript

Gestational hypertension

Preeclampsia

<0.0001

<0.0001

<0.0001

Author Manuscript

Figures are means (SD)
p-values from linear regression models:
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1

p-value for examining if timing of collection (<22, 22-32, 33-42 weeks) is a significant predictor,

2

p-value≤0.05 for comparing women in each pregnancy complication group to women in the control group,

3

Author Manuscript

p-value≤0.001 for comparing women in each pregnancy complication group to women in the control group.
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Table 3

Author Manuscript

Associations between maternal lipid biomarkers and neonatal anthropometrics by
pregnancy complication group at three measurements across gestation in the CPEP Study
β (95% CI)

Baseline <22 wk GA

Second 22-32 wk GA

Third 33-42 wks GA

2.23 (0.24, 4.22)

2.36 (0.38, 4.33)

2.55 (0.87, 4.22)1

Normal
Total cholesterol
Ponderal Index, kg/m3
Length, cm

-0.64 (-1.19, -0.099)

HDL
Ponderal Index, kg/m3
Length, cm

6.77 (1.13, 12.4)
-2.56 (-4.43, -0.68)1

-2.21 (-4.22, -0.19)

Author Manuscript

LDL
Ponderal Index, kg/m3

2.05 (0.49, 3.61)

Length, cm

-0.52 (-1.02, -0.009)

Triglycerides
Birth weight z-score

0.19 (0.004, 0.37)

Gestational diabetes
HDL
-1.16 (-1.92, -0.40)1

Birth weight z-score
Triglycerides
Birth weight z-score

0.21 (0.001, 0.42)

Gestational hypertension

Author Manuscript

Total cholesterol
Birth weight z-score

0.22 (0.032, 0.41)

Head Circumference, cm

0.32 (0.033, 0.60)

0.24 (0.008, 0.47)

LDL
Head Circumference, cm

0.35 (0.040, 0.67)

Triglycerides
Birth weight z-score

0.31 (0.018, 0.60)

0.29 (0.11, 0.48)1

Length, cm

0.24 (0.066, 0.41)1
0.45 (0.10, 0.80)

Preeclampsia
Total cholesterol
Length, cm

0.38 (0.059, 0.70)

Author Manuscript

HDL
Birth weight z-score

-0.49 (-0.97, -0.003)

-0.82 (-1.39, -0.25)1

Ponderal Index, kg/m3

-1.50 (-2.86, -0.13)

-2.56 (-4.08, -1.03)1

Head Circumference, cm

-1.33 (-2.29, -0.37)1
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LDL
Birth weight z-score

0.20 (0.008, 0.39)

Author Manuscript

Length, cm

0.40 (0.056, 0.75)

Lipoprotein A
Birth weight z-score

0.16 (0.034, 0.30)

Length, cm

0.30 (0.033, 0.57)

Linear regression models adjusted for race/ethnicity, BMI, smoking status, and week of gestational age of sample collection. Models examining
Ponderal index, head circumference, and length also adjusted for gestational age of delivery.
Only significant results are reported p-value <0.05.

1

p-value <0.01
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